Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy

American Journal of Gastroenterology

Volumn 91, Issue 5, 1996, Pages 1027-1030

  Jamal, Hyder ^a   Regenstein, Fredric ^a   Farr, Gist ^a   Perrillo, Robert P ^a,b  

^a OCHSNER MEDICAL CENTER   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CHOLESTASIS; GRAFT FAILURE; HEPATITIS; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL TIME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHOLESTASIS, INTRAHEPATIC; GANCICLOVIR; GRAFT REJECTION; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TIME FACTORS; VIRUS REPLICATION;

EID: 0029967082     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989;321:1014-22, 1092-9.
2. Todo S, Demetris AJ, Van Thiel DH, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-26.
3. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
4. Phillips MJ, Cameron R, Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol 1992;140:1295-308.
5. Benner KG, Lee RG, Keefe EB, et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992;103:1307-12.
6. Mason AL, Wick M, White HM, et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology 1993;105:237-44.
7. Lau JYN, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Evidence that HBV may be cytopathic in liver grafts. Gastroenterology 1992;102:956-62.
8. Angus P, Richards M, Bowden S, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. Gastroenterol Hepatol 1993;8:353-7.
9. Chisari FV, Filippi P, Buras J, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987;84:6909-13.
10. Tur-kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83: 1627-31.
11. Sagnelli E, Maio G, Felaco FM, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980;2:395-7.
12. Cote PJ, Korba BE, Steinberg H, et al. Cyclosporin A modulates the course of woodchuck hepatitis virus infection and induces chronicity. J Immunol 1991;146:3138-44.
13. Gish RG, Keeffe EB, Fang JWS, et al. Ganciclovir treatment of recurrent hepatitis B virus (HBV) infection in orthotopic liver transplant (OLT) recipients. Gastroenterology 1994;106:A899 (abstract).
14. Kruger M, Tillman HL, Trautwein CH, et al. Treatment of hepatitis B virus reinfection after liver transplantation with famciclovir. Hepatology 1994;20:130A (abstract).
15. Bartholomew M, Vicary C, Roach K, et al. Use of lamivudine in the treatment of recurrent hepatitis B infection post-liver transplantation. Gastroenterology 1995;108:A1030 (abstract).
16. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333: 1657-61.